Dimension doses first patient in Phase I/II trial of DTX301 for OTC deficiency
US-based biopharmaceutical firm Dimension Therapeutics has started dosing patients in a Phase I/II clinical trial of DTX301 to treat ornithine transcarbamylase (OTC) deficiency. (Source: Drug Development Technology)
Source: Drug Development Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news
Oragenics starts AG013 dosing in Phase II trial to treat oral mucositis
US-based antibiotics developer Oragenics has started dosing patients in a Phase II clinical trial of AG013 for the treatment of oral mucositis (OM). (Source: Drug Development Technology)
Source: Drug Development Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news
Otonomy ’s Phase III trial for M é ni è re's disease fails to meet endpoints
US-based Otonomy has reported results from a Phase III clinical trial (AVERTS-1) of its drug candidate Otividex (OTO-104) to treat patients with a chronic ear disorder called Unilateral M é ni è re ’s disease. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news
ProQR concludes QR-010 dosing in Phase Ib trial to treat cystic fibrosis
The Netherlands-based ProQR Therapeutics has concluded dosing patients in a Phase Ib clinical trial of QR-010 for the treatment of patients with cystic fibrosis. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news
Amgen ’s long-term analysis of Kyprolis’ ENDEAVOR trial shows favourable data
Amgen has reported positive data from a long-term analysis of the Phase III ENDEAVOR trial of Kyprolis (carfilzomib) for the treatment of relapsed or refractory multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news
PDG to Showcase Products at AAPS
Pharmaceutical Development Group has announced it will be attending this year's AAPS Annual Meeting and Exposition in San Diego. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news
Duzallo (allopurinol and lesinurad) for the Treatment of Hyperuricemia Associated with Gout
Duzallo (allopurinol and lesinurad) is indicated for the treatment of hyperuricemia associated with uncontrolled gout. It contains urate transporter-1 (URAT-1) inhibitor blended with xanthine oxidase inhibitor (XOI). (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news
Bayer starts enrolment for Phase III uterine fibroids trial in US
Bayer has started patient enrolment for a Phase III ASTEROID clinical trial of vilaprisan to treat patients with uterine fibroids in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news
Gliknik commences dosing in Phase II oral cavity cancer trial
US-based biopharmaceutical firm Gliknik has commenced patient dosing in a Phase II clinical trial of immunomodulatory therapeutic biropepimut-S (GL-0817) to prevent recurrence of oral cavity squamous cell cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news
Chi-Med begins Phase I trial of lymphoma drug in China
Hutchison China MediTech (Chi-Med) has begun a Phase I clinical trial of its therapeutic candidate HMPL-689 to treat patients with non-Hodgkin lymphoma in China. (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news
Pharmaceutical Development Group-Pharmaceutical Regulatory Consultant and FDA Regulatory Strategist
Pharmaceutical Development Group (PDG) provides pharmaceutical regulatory consulting to firms located around the world. (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news
Sangamo and Pfizer begin dosing in Phase I/II trial for haemophilia A
Sangamo Therapeutics and Pfizer have begun dosing patients in a Phase I/II clinical trial (Alta) of investigational gene therapy SB-525 to treat patients with a rare genetic blood disease known as haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - August 28, 2017 Category: Pharmaceuticals Source Type: news
Daiichi Sankyo and BMS to perform Phase Ib oncology combination trial
Daiichi Sankyo has entered a research collaboration to assess its investigational antibody drug conjugate (ADC) DS-8201 in combination with Bristol-Myers Squibb ’s (BMS) Opdivo (nivolumab) in a Phase Ib clinical trial to treat HER2-expressing metastat… (Source: Drug Development Technology)
Source: Drug Development Technology - August 28, 2017 Category: Pharmaceuticals Source Type: news
Anti-inflammatory drug minimises CV risk in Novartis ’ CANTOS trial
Novartis has reported positive primary results from its Phase III CANTOS clinical trial of ACZ885 (canakinumab) quarterly injections in patients with a history of heart attacks and inflammatory atherosclerosis. (Source: Drug Development Technology)
Source: Drug Development Technology - August 28, 2017 Category: Pharmaceuticals Source Type: news
Symic Bio starts enrolment in Phase II trial of osteoarthritis drug
Biopharmaceutical firm Symic Bio has started patient enrolment in a Phase II clinical trial (MODIFY2) of its product candidate SB-061 to treat osteoarthritis of the knee. (Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news
